Anti-hair loss composition and use thereof

Abstract

The present invention belongs to the field of biotechnology. More specifically, it relates to a new use of bakuchiol, specifically to the use of bakuchiol in enhancing the anti-hair loss efficacy of diaminopyrimidine oxides and their derivatives, wherein the diaminopyrimidine oxides and their derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and more specifically relates to a new use of bakuchiol, and more particularly to the use of bakuchiol in enhancing the anti-hair loss efficacy of diaminopyrimidine oxides and their derivatives. Background Art

[0002] Numerous studies have confirmed that diaminopyrimidine oxides can prevent hair loss and promote hair growth. They can react with sulfotransaminase to generate active diaminopyrimidine oxide sulfates. The active sulfate components play a role in preventing hair loss and promoting hair growth. The main mechanism is reflected in: (1) promoting angiogenesis and promoting capillary dilation, increasing blood flow to the body's hair follicles to promote hair growth; (2) stimulating the proliferation of hair follicle epithelial cells, improving the survival rate of scalp hair follicles, reducing hair follicle apoptosis, and promoting rapid hair growth; (3) promoting the formation of hair shafts throughout the hair follicle growth period; (4) reducing the damage of androgens to human hair follicles, preventing hair from becoming thin, soft, and falling off; (5) changing the trace elements in hair follicle cells and inhibiting the growth of hair follicles. [1] .

[0003] Bakuchiol is a natural compound extracted from the plant Psoralea corylifolia. Its IUPA C name is (1E,3S)-3-vinyl-3,7-dimethylocta-1,6-dien-4-ol and its molecular formula is C 18 H 24 O, a monoterpenoid compound, contains a phenolic hydroxyl group (-OH) and a ketone group (C=O). It possesses antioxidant and anti-inflammatory properties, with the structural formula shown in Equation 1. Bakuchiol has been shown to have the following effects: ① It can regulate retinoic acid receptors and downstream genes such as CIBP1 and TIG1, thus closely resembling the efficacy and mechanism of action of VA. ② It can promote collagen production, particularly type I and IV collagen, comparable to VA. ③ It can inhibit inflammatory factors and reduce inflammatory responses. ④ It can regulate the expression of aquaporins. In terms of proven clinical efficacy, such as wrinkle reduction, freckle reduction, and skin hydration, bakuchiol is not only comparable to VA but also offers the advantage of being less irritating. It is considered a natural alternative to retinol (vitamin A), but is milder and more stable. Currently, three companies in China have filed for public registration of this raw material: Sytheon Corporation, Yunnan Hengjin Pharmaceutical, and Guangdong Yuewei Microbiology. However, the current purpose of using bakuchiol is as a skin improver, such as skin protectant, skin feel regulator, moisturizer and antioxidant, and there is little research on the application of bakuchiol in other fields.

[0004]

[0005]

[0006] [1] Xi Baohu. Study on the Synthesis Process of Diaminopyrimidine Oxide Derivatives[D]. Tianjin: Qingdao University of Science and Technology, 2023.1~3. Summary of the Invention

[0007] Prior to the application date, no potential benefits of bakuchiol on the scalp and hair had been discovered. However, the inventors have confirmed that, although bakuchiol does not directly promote hair growth, it can enhance the anti-hair loss efficacy of diaminopyrimidine oxides, and thus the present invention was made.

[0008] One of the objects of the present invention is to provide a method for enhancing the anti-hair loss efficacy of diaminopyrimidine oxides and their derivatives.

[0009] In one embodiment of the present invention, the diaminopyrimidine oxide and its derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0010] In addition, the enhancing effect of bakuchiol was not observed in other substances with anti-hair loss effects listed in the embodiments of this article. Among these substances, finasteride has been found so far, and other substances are yet to be investigated.

[0011] In one embodiment of the present invention, the diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide. The reason for this preference is that, in experiments, it was found that among the listed diaminopyrimidine oxides and their derivatives, the combination of bakuchiol with 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide and 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide had the best anti-hair loss effect. In a mouse model of androgenic alopecia, the combined effect of the two was the best, and was far greater than the sum of the single use (1+1>2), resulting in a synergistic effect. Among the two, the combination with 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide had the best effect, and the water solubility of the combination with 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide was higher than that of 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, and the irritation was lower.

[0012] Furthermore, in these combined groups, significant improvement in hair quality was observed, as evidenced by a significant increase in hair diameter and cuticle length (see Figures 3-4 ), and this effect is weak or even unobservable when used alone.

[0013] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, and 1:1. In the combination of bakuchiol and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide, not all ratios can produce satisfactory effects. Experiments have shown that within a ratio of 1:0.1 to 1, the two exhibit additive or synergistic effects.

[0014] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5. Within the range of 1:0.1 to 1, when the ratio is 1:0.5, the synergistic effect of preventing hair loss and improving hair quality is the strongest.

[0015] Another object of the present invention is to provide an anti-hair loss composition, which comprises bakuchiol and diaminopyrimidine oxides and derivatives thereof.

[0016] In one embodiment of the present invention, the diaminopyrimidine oxide and its derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0017] In one embodiment of the present invention, the diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0018] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.1-1.

[0019] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, and 1:1.

[0020] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5. Within the range of 1:0.1 to 1, when the ratio is 1:0.5, the synergistic effect of preventing hair loss and improving hair quality is the strongest.

[0021] In one embodiment of the present invention, the composition can be prepared as a medicine or a cosmetic.

[0022] Another object of the present invention is to provide an anti-hair loss essence, which uses bakuchiol and 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide as main active ingredients.

[0023] In one embodiment of the present invention, in the essence, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, and 1:1. Furthermore, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5.

[0024] In one embodiment of the present invention, the anti-hair loss essence further includes other auxiliary ingredients commonly used in the art, including but not limited to: solvents, moisturizing ingredients, thickening ingredients, hair conditioning ingredients, skin conditioning ingredients, soothing ingredients, solubilizers, antioxidants, preservatives, pH regulators and fragrances.

[0025] In one embodiment of the present invention, the solvent is water, ethanol, denatured ethanol or a mixture thereof.

[0026] In one embodiment of the present invention, the moisturizing ingredient is one of lactic acid, arginine, sodium hyaluronate, glycerin, soybean oil, butylene glycol, 1,2-pentanediol, PCA magnesium, Egyptian blue water lily water, or a mixture thereof.

[0027] In one embodiment of the present invention, the thickening component is acrylates / beheneth-25 methacrylate copolymer.

[0028] In one embodiment of the present invention, the hair conditioning ingredient is one of cocoyl glutamate, pyridoxine hydrochloride, safflower glucoside, methionine, hydrolyzed wheat protein, or a mixture thereof.

[0029] In one embodiment of the present invention, the skin conditioning ingredient is one of adenosine triphosphate disodium, lavender (LAVANDULA HYBRIDA) oil, zucchini seed oil and watercress extract, or a mixture thereof.

[0030] In one embodiment of the present invention, the soothing ingredient is one of Amaranthus aviculare root extract, stearyl glycyrrhetinate, menthol, rhamnose and sage oil, or a mixture thereof.

[0031] In one embodiment of the present invention, the solubilizer is PEG-40 hydrogenated castor oil, PPG-1-PEG-9 lauryl glycol ether, or a mixture thereof.

[0032] In one embodiment of the present invention, the antioxidant ingredient is one of nasturtium extract, tocopheryl acetate, hesperidin methyl chalcone, lime oil, madecassoside and butylated hydroxytoluene, or a mixture thereof.

[0033] In one embodiment of the present invention, the preservative is one of sorbic acid, phenoxyethanol and benzyl alcohol, or a mixture thereof.

[0034] In one embodiment of the present invention, the pH adjuster is one of aminomethyl propanol, sodium citrate, disodium hydrogen phosphate and citric acid, or a mixture thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The hair growth scores of mice in each group were compared;

[0036] Figure 2 is the hair coverage rate of mice in each group on day 28;

[0037] Compared with the blank control group, * P<0.01; compared with the model group, # P<0.05, ## P < 0.01, ### P<0.001; compared with the Kopexil group, a P<0.05; compared with minoxidil group, b P<0.05; compared with the comparable group, c P<0.01.

[0038] Figure 3 Comparison of hair diameters of mice in each group on day 28;

[0039] Figure 4 Comparison of hair scale lengths of mice in each group on day 28;

[0040] in, Figure 3 and Figure 4 Compared with the model group, # P<0.05, ## P<0.01. DETAILED DESCRIPTION

[0041] The present invention is further described below with reference to specific examples, which, however, are not intended to limit the present invention in any way. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in the art.

[0042] Unless otherwise specified, the reagents and materials used in the following examples were commercially available.

[0043] Test Example 1: Efficacy Test

[0044] 1 Experimental part

[0045] 1.1 Experimental Materials: 2,4-diaminopyrimidine-3-oxide (Kopexil, purchased from Wuhan Belka Biopharmaceutical Co., Ltd.), 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide (Minoxidil, purchased from Wuhan Belka Biopharmaceutical Co., Ltd.), 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide (Copexil, purchased from Hubei Guangao Biotechnology Co., Ltd.); Bakuchiol (purchased from Sytheon).

[0046] 1.2 Experimental methods

[0047] 1.2.1 Animal grouping and coating method: 110 male C57BL / 6 mice were selected. After acclimating to the environment for 1 week, they were numbered according to their weight and divided into 11 groups according to their weight using Excel software and a stratified randomized block design method: blank control group, hair loss model group, 2wt% bakuchiol group, 1wt% Kopexil group, 1wt% minoxidil group, 1wt% cobiquinol group, 1wt% finasteride group, 2wt% bakuchiol + 1wt% Kopexil group, 2wt% bakuchiol + 1wt% minoxidil group, 2wt% bakuchiol + 1wt% cobiquinol group and 2wt% bakuchiol + 1wt% finasteride group, with 10 mice in each group.

[0048] Mix rosin and paraffin wax in a ratio of 1:1, heat and melt, cool to a suitable temperature, and evenly apply to an area of ​​about 4cm×4cm on the back of the mouse. After cooling and solidifying, peel it off to induce the growth of the mouse hair follicles. At this time, the hair follicles are morphologically the same as the spontaneously formed growth follicles, and the skin appears pink. On the second day of hair removal, anesthetize the mice, and apply 0.1mL·cm -2 Apply 50% ethanol solution once a day for 28 consecutive days; mice in other groups were all applied with a concentration of 1 mg·mL -1Testosterone solution was administered once daily for 28 consecutive days. Thirty minutes after modeling each day, the matrix solution was applied to the hair removal area of ​​mice in the blank and model groups using a cotton swab. The other drug groups were topically applied with the corresponding drug solution, with a dosing volume of 0.2 mL per mouse.

[0049] 1.2.2 Preparation of drug solutions: ① Matrix solution: Weigh 95% ethanol, propylene glycol, and pure water in a mass ratio of 3:6:2 and mix thoroughly to obtain a matrix solution; ② Bakuchiol group, Kopexil group, minoxidil group, clopidogrel group, and finasteride group: Weigh the corresponding weight of each drug, add it to the matrix solution and dissolve it evenly to obtain a drug solution; ③ Combination group: Weigh the corresponding weight of each substance and dissolve it in the matrix solution to obtain drug solutions of 2 wt% bakuchiol + 1 wt% Kopexil, 2 wt% bakuchiol + 1 wt% minoxidil, 2 wt% bakuchiol + 1 wt% clopidogrel, and 2 wt% bakuchiol + 1 wt% finasteride.

[0050] 1.2.3 Hair growth rate measurement: Observe the skin color changes and hair growth of the mice. Take photos after anesthesia on days 0, 7, 14, 21, and 28. Refer to the scoring criteria and combine the actual situation to score the hair growth of each mouse according to Table 1.

[0051] Table 1 Hair growth scoring criteria

[0052] Fraction Scoring Criteria 1 The skin is pink, which is the state just after hair removal. The red color is more obvious, and the hair follicles are in the resting phase. 2 The skin is pinkish white, with less redness but no gray yet. The hair follicles begin to enter the early growth stage. 3 The skin is white with obvious gray appearing but no black yet. The hair follicles are in the early stages of growth. 4 The skin is gray and partially black, with occasional short hairs, indicating that the hair follicles are in the middle growth phase. 5 The skin is dark grey and covered with short hair, and the hair follicles are in the middle and late stages of growth; 6 points Indicates that the skin is covered with long black hair, and the hair follicles are in the late growth stage

[0053] According to the above scoring criteria, three individuals scored the mice's hair growth, and the average score was taken as the final score. On day 28, the hair coverage area and the area of ​​hair loss in the mice's hair loss region were measured using Image J software and calculated using the following formula.

[0054] Hair coverage (%) = hair coverage area / hair removal area × 100%

[0055] 1.2.3 Hair length measurement: On the 29th day, mice were killed and new hair (>20 hairs) was randomly plucked from three hair-depleted areas using tweezers. The 20 longest hairs were spread out on white paper and measured with a vernier caliper to record the average new hair length of the mice.

[0056] 1.2.4 Hair quality measurement: Newly grown hair from the depilated area was randomly selected and photographed using a scanning electron microscope (SEM). The mid-end diameter of the hair in the image was measured using Image J to evaluate hair thickness. The length of the hair cuticle at the mid-end was measured to evaluate hair cuticle size. The quality of the newly grown hair in the mice was comprehensively evaluated.

[0057] 1.2.5 HE staining to determine the number of hair follicles: After killing mice, the skin of the depilated area was excised and fixed in 4% paraformaldehyde tissue fixative for at least 24 hours. After dehydration, the skin was embedded in paraffin, sectioned, dehydrated, stained with hematoxylin and eosin, and mounted. The slides were observed under a light microscope (×100) and the results were recorded. The number of hair follicles in the HE-stained images of each group was counted using the counting function of Image J. Six fields of view were obtained for each group, and the average value was calculated.

[0058] 2 Results and Discussion

[0059] 2.1 Hair growth rate

[0060] The hair growth scores of the depilatory areas of each group of mice are shown in Figure 1 , hair coverage see Figure 2 Analysis showed that compared with the blank group, the hair growth in the model group became significantly slower, and the difference in growth rate became gradually obvious on the 14th day. Compared with the model group, the hair growth rate of mice in the Kopexil group, minoxidil group, cocamidopropyl betaine group, and finasteride group was significantly faster. In the combination group, except for the combination of bakuchiol + finasteride, the hair growth rate of mice in the other groups was higher than when using either alone, and the difference was significant. This shows that bakuchiol can enhance the hair growth effect of Kopexil, minoxidil, and cocamidopropyl betaine.

[0061] 2.2 Hair length and number of hair follicles

[0062] As can be seen from the table below, the hair length and hair follicle number of mice in each model group were significantly reduced compared with the blank control group (P < 0.01); compared with the model group, the hair length and hair follicle number of the bakuchiol group increased, but no significant difference was seen, while the hair length and hair follicle number of mice in the Kopexil, minoxidil, copiclone and finasteride groups were significantly or extremely significantly increased compared with the model group; and in the combination group, except for the finasteride group, the hair length and hair follicle number of mice in the other groups were extremely significantly higher than those in the single-use group, and the difference was significant, especially in the bakuchiol + copiclone group and the bakuchiol + minoxidil group. The combined effect of the two was much greater than the sum of the single use (1+1>2), resulting in a synergistic effect.

[0063] Table 2 Hair length and number of hair follicles

[0064]

[0065]

[0066] Compared with the blank group, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01; compared with the Kopexil group,a P<0.05; compared with minoxidil group, b P<0.01; compared with the comparable group, c P<0.01.

[0067] 2.3 Hair quality

[0068] Comparison of hair diameter in the hair removal area of ​​each group of mice Figure 3 , the length of hair scales is relatively Figure 4 There was no significant difference in hair diameter and hair scale length between the model group, Kopexil group, minoxidil group, cocamidopropyl group and finasteride group and the blank group. However, the hair diameter and hair scale length of the mice in the bakuchiol and bakuchiol combined groups increased significantly, which indicates that bakuchiol can not only enhance the effect of diaminopyrimidine oxides in promoting hair regeneration, but also improve the quality of new hair.

[0069] Experimental Example 2: Verification of the Hair Growth-Promoting Effects of Bakuchiol and Kopi Lucidum at Different Mass Ratios

[0070] Experiment 1 verified that the combination of bakuchiol and copicula has the best anti-hair loss effect. Referring to the method of Experiment 1, we further investigated the effects of different ratios of bakuchiol and copicula on the hair growth rate and number of hair follicles in the androgenic alopecia mouse model. The results are shown in Table 3 below.

[0071] Table 3 Test results

[0072] Group Hair length (mm) Average number of hair follicles Hair coverage (%) Blank control group 6.562±0.438 49.67±1.75 90.36±8.68 Model Group <![CDATA[4.351±0.215 ** ]]> <![CDATA[19.83±2.32 ** ]]> <![CDATA[31.46±2.37 ** ]]> Bakuchiol group 4.482±0.304 20.91±1.35 33.18±3.25 Comparable group <![CDATA[4.729±0.221 # ]]> <![CDATA[24.50±2.11 ## ]]> <![CDATA[55.29±5.23 ## ]]> Bakuchiol + Coleus (1:0.1) <![CDATA[5.347±0.115 ^ ]]> <![CDATA[31.00±1.06 ^ ]]> <![CDATA[70.15±3.92 ^^ ]]> Bakuchiol + Coleus (1:0.2) <![CDATA[5.564±0.136 ^^ ]]> <![CDATA[32.83±1.33 ^ ]]> <![CDATA[72.27±2.08 ^^ ]]> Bakuchiol + Coleus (1:0.5) <![CDATA[6.262±0.442 ^^ ]]> <![CDATA[46.00±1.28 ^^ ]]> <![CDATA[83.48±5.33 ^^ <!-- 6 -->]]> Bakuchiol + Coleus (1:0.7) <![CDATA[6.041±0.259 ^^ ]]> <![CDATA[41.00±1.53 ^^ ]]> <![CDATA[81.05±4.39 ^^ ]]> Bakuchiol + Coleus (1:1) <![CDATA[5.734±0.226 ^^ ]]> <![CDATA[36.33±1.21 ^^ ]]> <![CDATA[78.55±3.05 ^^ ]]> Bakuchiol + Coleus (0.1:1) <![CDATA[5.156±0.186 ^ ]]> <![CDATA[28.17±2.03 ^ ]]> <![CDATA[62.44±1.97 ^ ]]> Bakuchiol + Coumarin (0.2:1) <![CDATA[5.123±0.371 ^ ]]> <![CDATA[29.67±1.32 ^ ]]> <![CDATA[65.37±3.55 ^ ]]> Bakuchiol + Coleus (0.5:1) <![CDATA[5.329±0.105 ^ ]]> <![CDATA[32.17±2.11 ^ ]]> <![CDATA[74.40±4.16 ^^ ]]> Bakuchiol + Coumarin (0.7:1) <![CDATA[5.557±0.244 ^^ ]]> <![CDATA[33.83±1.59 ^ ]]> <![CDATA[75.29±4.03 ^^ ]]>

[0073] Compared with the blank group, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01; compared with the comparable group, ^ P<0.05, ^^ P<0.01.

[0074] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be considered as equivalent replacement methods and are included in the scope of protection of the present invention.

Claims

1. The use of bakuchiol in the preparation of a drug for enhancing the anti-hair loss efficacy of diaminopyrimidine oxides and their derivatives; the diaminopyrimidine oxides and their derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

2. The use according to claim 1, characterized in that The diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

3. The use according to claim 2, characterized in that The weight ratio of bakuchiol to 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide is 1:0.1~1.

4. The use according to claim 3, characterized in that The weight ratio of bakuchiol to 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide is 1:0.

5.

5. An anti-hair loss composition, characterized in that The composition comprises bakuchiol and diaminopyrimidine oxides and derivatives thereof; the diaminopyrimidine oxides and derivatives thereof are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

6. The anti-hair loss composition according to claim 5, characterized in that The diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

7. An anti-hair loss essence, characterized in that: The main active ingredients are bakuchiol and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

8. The anti-hair loss essence according to claim 7, characterized in that In the essence, the weight ratio of bakuchiol to 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide is 1:0.1~1.

Images